According to the Pharma Tesco announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 30% for 3 consecutive trading days from July 13 to 15, 2026, which was an abnormal fluctuation. Revenue for 2025 was 4.454 billion yuan, up 1.35% year on year, net loss was 12.8515 million yuan, down 197.36% year on year; revenue for the first quarter of 2026 was 1,114 billion yuan, down 2.08% year on year, and net loss was 2.702 million yuan, down 165.02% year on year. Affected by policy and other factors, performance declined, and profits were uncertain. The company is promoting disclosure of financial information after correcting accounting errors to remind investors to be aware of transaction risks.

According to the Pharma Tesco announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 30% for 3 consecutive trading days from July 13 to 15, 2026, which was an abnormal fluctuation. Revenue for 2025 was 4.454 billion yuan, up 1.35% year on year, net loss was 12.8515 million yuan, down 197.36% year on year; revenue for the first quarter of 2026 was 1,114 billion yuan, down 2.08% year on year, and net loss was 2.702 million yuan, down 165.02% year on year. Affected by policy and other factors, performance declined, and profits were uncertain. The company is promoting disclosure of financial information after correcting accounting errors to remind investors to be aware of transaction risks.